Acumen Pharmaceuticals, Inc. ABOS

2.24 0.00 0.00% as of 25 Sep
Market cap
$161.6M
P/E
0.0×
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
5.77 3.89 4.39 2.35
Current Ratio
6.02 4.07 4.55 2.47
Net Debt/EBITDA
3.59 3.42 4.62 2.40
Debt/Assets
21.55% 25.37% 23.23% 27.21%
Debt/Equity
0.33 0.44 0.35 0.55
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
1.15 0.76 1.16 0.55
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.50) (0.32) (0.38) (0.25)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.50) (0.32) (0.38) (0.25)
Cash per Share
2.09 1.93 2.03 1.53
Shareholders Equity per Share
1.54 1.16 1.38 0.79
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
1.54 1.16 1.38 0.79
Free Cash Flow
(30.49) (19.10) (24.13) (18.07)
Working Capital
110.20 92.25 103.87 68.67
Capital Expenditures
0.00 0.00 — —
Net Current Asset Value
83.11 69.85 86.94 56.77
EV/EBIT
— — — —
Capex to Sales
0.00 0.00 — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Payables
1.51 3.10 1.36 7.74
Average Assets
204.60 180.91 169.05 143.95
Average Common Equity
155.19 126.12 121.50 87.17

Fold the line items

Columns are period end dates